|

Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients

RECRUITINGSponsored by Antonio Bellasi
Actively Recruiting
SponsorAntonio Bellasi
Started2024-10-12
Est. completion2025-10-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06668831

Summary

Despite recent progress in the field of hemodialysis (HD), mortality remains unacceptably high, particularly due to cardiac arrhythmias. Recent evidence suggests that fibroblast growth factor 23 (FGF23) is implicated in the pathogenesis of cardiac arrhythmias and sudden death. However, several aspects of both the pathogenetic mechanism(s) as well as the actual association in individuals with Chronic Kidney Disease (CKD) and the effect of dialysis clearance of FGF23 need to be elucidated. The investigators aim at testing the independent association of FGF23 changes due to dialysis removal and electrocardiographic (ECG) abnormalities (namely QTc prolongation) in a well characterized sample of patients undergoing maintenance HD. The study will be developed in the Division of Nephrology, Ente Ospedaliero Cantonale.

Eligibility

Age: 18 Years+Healthy volunteers accepted
The study envisages the enrolment of:

* Adult subjects (\>18 years of age) who can sign an informed consent.
* on maintenance HD (for at least 3 months)

Exclusion Criteria:

* history of cardiac arrhythmias at study recruitment define as atrial fibrillation or pace-maker assisted cardiac rhythm

Conditions2

Heart DiseaseHemodialysis

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.